Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 3/20 | 0.43 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 5/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20299476 | 0.92 | MAPK8 (0.43) | MAPK1TYRO3SELPKMT2AMERTK | |
| SCHEMBL21591892 | 0.92 | MAPK8 (0.43) | MAPK1TYRO3SELPKMT2AMERTK | |
| SCHEMBL21593678 | 0.92 | MAPK8 (0.43) | MAPK1TYRO3SELPKMT2AMERTK | |
| SCHEMBL29501867 | 0.92 | MAPK8 (0.43) | MAPK1TYRO3SELPKMT2AMERTK | |
| SCHEMBL10050287 | 0.90 | KMT2A (0.50) | TYRO3KMT2AMERTKAXLFLT3 | |
| SCHEMBL31612124 | 0.90 | KMT2A (0.50) | TYRO3KMT2AMERTKAXLFLT3 | |
| Fluoride SCHEMBL13518132 | 0.89 | KMT2A (0.57) | TYRO3KMT2AMERTKAXLFLT3 | |
| SCHEMBL13518145 | 0.87 | KMT2A (0.58) | MAPK1TYRO3KMT2AMERTKAXL | |
| SCHEMBL31612129 | 0.87 | KMT2A (0.55) | KMT2AAXLSYK | |
| SCHEMBL762040 | 0.87 | KMT2A (0.55) | KMT2AAXLSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977966-A | DNA-PK/PARP1 double-target inhibitor and preparation method and application thereof | 赣南医科大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025049481-A1 | METHODS OF EDITING AN HLA-A GENE IN VITRO | INTELLIA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240391921-A1 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | INTELLIA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| EP-4406955-A1 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-113493471-B | Heteroaromatic kinase inhibitors | 山东轩竹医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-117940426-A | DNA-dependent protein kinase inhibitors, compositions and uses thereof | 英特利亚治疗股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| EP-4323360-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | Intellia Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| EP-3558997-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK1 883/4885TYRO3 692/4885SELP 1818/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | MAPK1 1323/4885TYRO3 4268/4885SELP 1889/4885 |
| US-20240391921-A1 | CRYSTAL FORM OF IMIDAZOLINONE DERIVATIVE | WEE1, WEE2, TOP1 | MAPK1 433/4885TYRO3 3849/4885SELP 3650/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK1 883/4885TYRO3 692/4885SELP 1818/4885 |
| US-20240300977-A1 | INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND USES THEREOF | CHEK1, DCK, CHEK2 | MAPK1 128/4885TYRO3 1713/4885SELP 4826/4885 |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK1 883/4885TYRO3 692/4885SELP 1818/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK1 883/4885TYRO3 692/4885SELP 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.